Alnylam Pharmaceuticals, Inc. (ALNY) said Wednesday that the ENVISION Phase 3 study of givosiran met its primary efficacy endpoint and the majority of secondary endpoints. Givosiran is an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria or AHP.
from RTT - Biotech https://ift.tt/2Tx246l
via IFTTT
No comments:
Post a Comment